CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies.
The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively.
Under the terms of this global licensing agreement, CBT gains access to a third checkpoint inhibitor to complement the existing immuno-oncology pipeline of PD-1 and PD-L1 inhibitors. CrownBio is eligible to receive potential future development, regulatory and sales-based milestones payments over $47 M, as well as royalties on net sales. Once the recommended Phase 1 monotherapy portion of the Phase 1/2 trial is completed, combination with other complementary therapies in CBT's immuno-oncology and targeted therapy portfolios will be initiated.
"This acquisition from CrownBio is another building block in our strategy to develop a portfolio of programs in combination with our pipeline of immuno-oncology and targeted therapies that we believe will lead to a meaningful durable clinical benefit and impact on cancer survival in variety of malignancies and in larger proportion of cancer patients," said Sanjeev Redkar, PhD, Chief Executive Officer and President of CBT. He continued, "The CTLA-4 asset fits well with our ongoing clinical studies and we hope to advance an additional three single agent and two combination clinical trials are expected to enter the clinic by the end of 2018."
Tillman Pearce, MD, Interim Chief Medical Officer, added "The CTLA-4 asset demonstrated stronger binding and its performance in nonclinical models compares quite favorably to the marketed CTLA-4 which may allow for differentiation in the clinic."
Dr. Jean Pierre Wery, CEO of CrownBio stated, "CrownBio enables biopharmaceutical clients and partners the scientific platform to advance drugs to market to improve treatment options to patients. This includes strategic licensing of proprietary antibodies. We are pleased to support CBT's innovative immuno-oncology pipeline by licensing our CTLA-4 recombinant, human monoclonal antibody."
About CBT Pharmaceuticals, Inc.
CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company committed to becoming a global leader in the discovery and development of oncology combination therapies by focusing on therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. The acquisition of the CTLA-4 compliments the company's existing pipeline of four development-stage assets. CBT has two novel humanized monoclonal antibodies - CBT-501, targeting the Programmed Death-1 (PD-1) membrane receptor of immune cells, as well as Programmed Death Ligand-1 (PD-L1) (CBT-502) that restores the body's immune system to recognize and kill cancer cells. In addition, CBT-101, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pathway and CBT-102, an oral multi-targeted kinase inhibitor that targets uncontrolled growth signaling pathways. The company was founded in 2016. For more information, please visit www.cbtpharma.com and follow us on Twitter @CBTpharma.
About Crown Bioscience, Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
MacDougall Biomedical Communications
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
VITEC's EZ TV Video Wall Solution Wins Best of Show Award at the 2018 NAB Show26.4.2018 19:00 | Pressmeddelande
VITEC's EZ TV Video Wall Solution Wins Best of Show Award at the 2018 NAB Show SUNNYVALE, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- VITEC, a worldwide leader in advanced video encoding and streaming solutions, today announced that the new EZ TV video wall processor, available within the award-winning EZ TV IPTV and Digital Signage Platform, was recognized with a Best of Show Award at the 2018 NAB Show from Sound & Video Contractor (SVC) magazine. Evaluated by a panel of industry experts, the Best of Show Award winners were selected based on innovation, feature set, cost efficiency, and performance in serving the industry. VITEC's video wall solution is designed to simplify deployment and management of projects involving IPTV, digital signage, and video wall content, while delivering a breathtaking visual experience. The new EZ TV video wall processors are 100 percent hardware-based, feature low-latency native playback of IPTV streams up to 4K, and support interactive content, video, a
Inspiration in Receipt of Crypto Currency Proposal26.4.2018 16:54 | Pressmeddelande
TORONTO, April 26, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) is pleased to announce that it is contemplating upon the request of Compassion Cannabis that it is allowed to accept crypto currency for settlement for any transactions that occur. The logic is that it would make for easy settlement in any jurisdiction. The Company is not adverse to this proposal, but must perform its due diligence and will table the matter at the AGM. Compassion Cannabis is an Ontario Corp., which has expertise to forward various facets of the explosive new market of the marijuana industry, including but not limited to the "Vape" market and dispensary centers for the industry. We believe this will be an extremely lucrative space with tremendous demand in the medical cannabis industry. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not revi
SNOMED International Announces Brazil as its 33rd Member26.4.2018 15:12 | Pressmeddelande
London, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- Brazil's Ministry of Health and SNOMED International announce that as of April 1, 2018, Brazil has joined the organization as SNOMED International's thirty-third Member. With SNOMED CT already used in various parts of the country, Brazil joined SNOMED International to support nationwide health system transformation as a foundational element of its ehealth Strategy, digiSUS. As outlined in this national strategy, the SUS Monitoring and Evaluation Department of Brazil's Ministry of Health is responsible overall for governance of the National Electronic Health Strategy and its related evaluation and development. Demonstrated through its membership in SNOMED International, Brazil has defined SNOMED CT as the chosen international reference terminology for use in its clinical systems supporting the national ehealth strategy. SNOMED CT is the world's most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOME
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 201826.4.2018 14:30 | Pressmeddelande
Management to host conference call WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2018 on Thursday, May 3, 2018. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 8885379. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 30 days. About Minerva Neurosciences Mine
Talend Data Fabric Now Certified on MapR Converged Data Platform Version 6.026.4.2018 14:11 | Pressmeddelande
Latest Release of Talend's Data Integration Platform Enables Powerful New Use Cases in Data Privacy, Compliance Monitoring, Claims Processing, Retail Optimization, and More REDWOOD CITY, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud and big data integration solutions, announced that the latest version of Talend Data Fabric is now certified for version 6.0 of the MapR Converged Data Platform, including MapR-DB and MapR-FS. The MapR Converged Data Platform is the industry's only enterprise-grade software solution that unifies big data and open source technologies with fast, native access to global event streaming, real-time database capabilities, and web-scale storage. Together, Talend and MapR provide a unified, open source-based data storage and management platform for an array of different applications, enabling organizations to harness big data in valuable ways to drive innovation and further their digital transformations. "Talend's powerf
CrownBio Launches New Humanized Target Model for Immunotherapy26.4.2018 14:00 | Pressmeddelande
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM(TM)) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs. Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University. The CD3E model expresses the human form of CD3E and is phenotypically normal with levels
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum